TB

Tierney Baum

Person

Heard in 2 episodes across 1 show since Oct 2026

Tierney Baum is a life-sciences journalist and editor covering biotechnology and pharmaceutical development.

Episodes

2
across 1 show

First heard

Oct 2026

Guest appearances

1

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20260
Oct 20261
Nov 20261

Email alert

Email me when Tierney Baum comes up on a podcast

One email a week at most, with the new episodes that mention Tierney Baum. Free, no account needed, unsubscribe in one click.

What Tierney Baum has said on podcasts

9 statements

  1. on Merck and Moderna personalized neoantigen vaccinePositiveNov 17, 2026· BioCentury This Week

    Merck and Moderna’s personalized neoantigen vaccine modality met a late-stage trial objective.

    “this modality could meet in a late stage trial.”

    Listen at 9:45

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  2. on personalized neoantigen vaccinesNeutralNov 17, 2026· BioCentury This Week

    The neoantigen vaccine field likely needs several years for solid answers.

    “we're probably still a ways out a couple years out from beginning to really get more solid answers to some of these questions”

    Listen at 11:58

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  3. on ModernaPositiveNov 17, 2026· BioCentury This Week

    Moderna and Merck’s neoantigen program leads the pipeline with the most Phase 3 trials.

    “they're still clearly ahead in the pipeline. They have the most phase three trials.”

    Listen at 12:23

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

2 episodes featuring Tierney Baum, newest first